Literature DB >> 11229517

Specificity of TLS-CHOP rearrangement for classic myxoid/round cell liposarcoma: absence in predominantly myxoid well-differentiated liposarcomas.

C R Antonescu1, A Elahi, M Humphrey, M Y Lui, J H Healey, M F Brennan, J M Woodruff, S C Jhanwar, M Ladanyi.   

Abstract

Myxoid liposarcoma (LS), the most common subtype of LS, is known to be characterized by the specific t(12;16) resulting in a TLS-CHOP fusion in almost all cases. We wished to address the following questions: (i) Is this genetic hallmark also present in other types of LS with predominant myxoid change? (ii) What is the proportion of cases with the variant EWS-CHOP fusion? (iii) What is the optimal approach for Southern blot detection of TLS breakpoints? We identified 59 LS characterized histologically by >90% myxoid component, in which frozen tissue tumor was available for DNA extraction. These 59 LS with myxoid features were divided into 2 groups: 42 LS with classic myxoid/round cell appearance (myxoid LS) and 17 well-differentiated LS (WDLS) with a predominant (>90%) myxoid component. Within the myxoid LS group, 29 tumors were low grade and 13 high grade (>20% round cell component). Among the 17 predominantly myxoid WDLS, there were 15 low grade and 2 focally high grade tumors. In addition, we selected as control group, 20 LS of other histological types with minimal or no myxoid change (17 WDLS and 3 pleomorphic LS) and 13 myxofibrosarcomas. Southern blot analysis was performed in all cases using a CHOP cDNA probe, and in all CHOP rearranged cases using a TLS cDNA probe. Probe/enzyme combinations for Southern blot analysis were CHOP exon 3-4 cDNA probe with BamHI or SacI, TLS exon 3-6 cDNA probe with BclI. All 42 cases of myxoid LS showed a CHOP rearrangement and 38 of them also had a TLS rearrangement. Among the 4 myxoid LS without Southern blot evidence of TLS rearrangement, 1 showed an EWS-CHOP fusion by Southern blotting and reverse transcriptase-polymerase chain reaction and in another case, reverse transcriptase-polymerase chain reaction detected a TLS-CHOP fusion transcript. None of the predominantly myxoid WDLS and none of the tumors included in the control group showed rearranegements with CHOP probe. In addition, 12 predominantly myxoid WDLS, 10 other LS, and 5 myxofibrosarcoma from the control group were also tested for TLS rearrangement; all were negative. The TLS-CHOP fusion is highly sensitive and specific for the entity of classic myxoid/round cell LS. Other types of LS, even with a predominant myxoid component, lack the TLS-CHOP rearrangement, confirming that they represent a genetically distinct group of LS. The prevalence of the EWS-CHOP variant fusion was approximately 2% in this series. The optimal enzyme for TLS genomic breakpoint detection is BclI.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11229517      PMCID: PMC1906905          DOI: 10.1016/S1525-1578(10)60628-9

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  31 in total

1.  Dedifferentiated myxoid liposarcoma: a clinicopathological study suggesting a closer relationship between myxoid and well-differentiated liposarcoma.

Authors:  T Mentzel; C D Fletcher
Journal:  Histopathology       Date:  1997-05       Impact factor: 5.087

2.  Cytogenetic findings in liposarcoma correlate with histopathologic subtypes.

Authors:  C Sreekantaiah; C P Karakousis; S P Leong; A A Sandberg
Journal:  Cancer       Date:  1992-05-15       Impact factor: 6.860

3.  Monoclonality of multifocal myxoid liposarcoma: confirmation by analysis of TLS-CHOP or EWS-CHOP rearrangements.

Authors:  C R Antonescu; A Elahi; J H Healey; M F Brennan; M Y Lui; J Lewis; S C Jhanwar; J M Woodruff; M Ladanyi
Journal:  Clin Cancer Res       Date:  2000-07       Impact factor: 12.531

4.  Oncogenic transformation and inhibition of adipocytic conversion of preadipocytes by TLS/FUS-CHOP type II chimeric protein.

Authors:  M Kuroda; T Ishida; M Takanashi; M Satoh; R Machinami; T Watanabe
Journal:  Am J Pathol       Date:  1997-09       Impact factor: 4.307

5.  Multifocal extremity sarcoma: an uncommon and controversial entity.

Authors:  S L Blair; J J Lewis; D Leung; J Woodruff; M F Brennan
Journal:  Ann Surg Oncol       Date:  1998 Jan-Feb       Impact factor: 5.344

6.  Characteristics of genomic breakpoints in TLS-CHOP translocations in liposarcomas suggest the involvement of Translin and topoisomerase II in the process of translocation.

Authors:  H Kanoe; T Nakayama; T Hosaka; H Murakami; H Yamamoto; Y Nakashima; T Tsuboyama; T Nakamura; D Ron; M S Sasaki; J Toguchida
Journal:  Oncogene       Date:  1999-01-21       Impact factor: 9.867

7.  CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant-negative inhibitor of gene transcription.

Authors:  D Ron; J F Habener
Journal:  Genes Dev       Date:  1992-03       Impact factor: 11.361

8.  Human translocation liposarcoma-CCAAT/enhancer binding protein (C/EBP) homologous protein (TLS-CHOP) oncoprotein prevents adipocyte differentiation by directly interfering with C/EBPbeta function.

Authors:  G Adelmant; J D Gilbert; S O Freytag
Journal:  J Biol Chem       Date:  1998-06-19       Impact factor: 5.157

9.  Detection of TLS/FUS-CHOP fusion transcripts in myxoid and round cell liposarcomas by nested reverse transcription-polymerase chain reaction using archival paraffin-embedded tissues.

Authors:  M Hisaoka; S Tsuji; Y Morimitsu; H Hashimoto; S Shimajiri; S Komiya; M Ushijima
Journal:  Diagn Mol Pathol       Date:  1998-04

10.  Analysis of FUS-CHOP fusion transcripts in different types of soft tissue liposarcoma and their diagnostic implications.

Authors:  F Willeke; R Ridder; G Mechtersheimer; M Schwarzbach; A Duwe; J Weitz; T Lehnert; C Herfarth; M von Knebel Doeberitz
Journal:  Clin Cancer Res       Date:  1998-07       Impact factor: 12.531

View more
  25 in total

1.  A novel type of EWS-CHOP fusion gene in two cases of myxoid liposarcoma.

Authors:  Taisuke Hosaka; Yasuaki Nakashima; Katsuyuki Kusuzaki; Hiroaki Murata; Tomitaka Nakayama; Takeharu Nakamata; Tomoki Aoyama; Takeshi Okamoto; Kohichi Nishijo; Nobuhito Araki; Tadao Tsuboyama; Takashi Nakamura; Junya Toguchida
Journal:  J Mol Diagn       Date:  2002-08       Impact factor: 5.568

2.  Paratesticular dedifferentiated liposarcoma with prominent myxoid stroma: report of a case and review of the literature.

Authors:  Shogo Tajima; Kenji Koda
Journal:  Med Mol Morphol       Date:  2015-05-19       Impact factor: 2.309

3.  Variation in myxoid liposarcoma: Clinicopathological examination of four cases with detectable TLS-CHOP or EWS-CHOP fusion transcripts whose histopathological diagnosis was other than myxoid liposarcoma.

Authors:  Kayo Suzuki; Yoshito Matsui; Nobuyuki Hashimoto; Norifumi Naka; Nobuhito Araki; Tomoatsu Kimura; Hideki Yoshikawa; Takafumi Ueda
Journal:  Oncol Lett       Date:  2011-11-15       Impact factor: 2.967

4.  Dedifferentiated liposarcoma of the deep (paralaryngeal) soft tissue: lessons learnt from a case with a partly deceptively benign appearing dedifferentiated component.

Authors:  Fredrik Petersson; Euan Murugasu
Journal:  Head Neck Pathol       Date:  2013-07-06

5.  Imaging appearance of well-differentiated liposarcomas with myxoid stroma.

Authors:  Yoav Morag; Corrie Yablon; Monica Kalume Brigido; Jon Jacobson; David Lucas
Journal:  Skeletal Radiol       Date:  2018-04-16       Impact factor: 2.199

6.  The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells.

Authors:  Katarina Engström; Helena Willén; Christina Kåbjörn-Gustafsson; Carola Andersson; Marita Olsson; Melker Göransson; Sofia Järnum; Anita Olofsson; Elisabeth Warnhammar; Pierre Aman
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

Review 7.  Gene translocations in musculoskeletal neoplasms.

Authors:  Balaji Krishnan; Gaurav Khanna; Denis Clohisy
Journal:  Clin Orthop Relat Res       Date:  2008-06-20       Impact factor: 4.176

8.  Metastatic myxoid liposarcomas: imaging and histopathologic findings.

Authors:  Kenneth Sheah; Hugue A Ouellette; Martin Torriani; G Petur Nielsen; Susan Kattapuram; Miriam A Bredella
Journal:  Skeletal Radiol       Date:  2007-12-21       Impact factor: 2.199

9.  Hyperexpression of HOXC13, located in the 12q13 chromosomal region, in well‑differentiated and dedifferentiated human liposarcomas.

Authors:  Monica Cantile; Francesca Galletta; Renato Franco; Gabriella Aquino; Giosuè Scognamiglio; Laura Marra; Margherita Cerrone; Gabriella Malzone; Angela Manna; Gaetano Apice; Flavio Fazioli; Gerardo Botti; Annarosaria De Chiara
Journal:  Oncol Rep       Date:  2013-10-01       Impact factor: 3.906

10.  CHOP 5'UTR-c.279T>C and +nt30C>T variants are not associated with overweight condition or with tumors/cancer in Italians - a case-control study.

Authors:  Ramachandran Meenakshisundaram; Nunzia Piumelli; Laura Pierpaoli; Claudia Gragnoli
Journal:  J Exp Clin Cancer Res       Date:  2009-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.